id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-1972-0010,FDA,FDA-2019-E-1972,Letter and Certificate from U.S. Patent and Trademark Office to Eli Lilly and Company,Other,Letter(s),2024-02-28T05:00:00Z,2024,2,2024-02-28T05:00:00Z,,2024-02-28T20:56:02Z,,0,0,090000648641df68
FDA-2019-E-1972-0009,FDA,FDA-2019-E-1972,Notice of Final Determination Letter,Other,Letter(s),2024-02-21T05:00:00Z,2024,2,2024-02-21T05:00:00Z,,2024-02-21T21:49:15Z,,0,0,09000064863eea1a
FDA-2019-E-1972-0008,FDA,FDA-2019-E-1972,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-17T05:00:00Z,2024,1,2024-01-17T05:00:00Z,,2024-01-17T19:20:52Z,,0,0,090000648639028e
FDA-2019-E-1972-0007,FDA,FDA-2019-E-1972,Letter from FDA CDER TO U.S. Patent and Trademark Office,Other,Letter(s),2023-11-15T05:00:00Z,2023,11,2023-11-15T05:00:00Z,,2023-11-15T19:48:15Z,,0,0,090000648627c3a8
FDA-2019-E-1972-0006,FDA,FDA-2019-E-1972,Determination of Regulatory Review Period for Purposes of Patent Extension; OLUMIANT,Notice,Determinations,2023-02-06T05:00:00Z,2023,2,2023-02-06T05:00:00Z,2023-04-08T03:59:59Z,2024-02-07T15:45:24Z,2023-02441,0,0,0900006485633dbd
FDA-2019-E-1972-0005,FDA,FDA-2019-E-1972,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2023-02-02T05:00:00Z,2023,2,2023-02-02T05:00:00Z,,2023-02-02T15:41:10Z,,0,0,090000648562cb74
FDA-2019-E-1972-0004,FDA,FDA-2019-E-1972,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T21:25:16Z,,0,0,090000648555faf0
FDA-2019-E-1972-0003,FDA,FDA-2019-E-1972,Letter from FDA to U.S. Patent and Trademark Office,Other,Letter(s),2019-06-21T04:00:00Z,2019,6,2019-06-21T04:00:00Z,,2019-06-21T14:49:41Z,,0,0,0900006483d31171
FDA-2019-E-1972-0001,FDA,FDA-2019-E-1972,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2019-04-24T04:00:00Z,2019,4,2019-04-24T04:00:00Z,,2019-04-24T14:52:03Z,,0,0,0900006483beaef2
FDA-2019-E-1972-0002,FDA,FDA-2019-E-1972,Patent Extension Application from Eli Lilly & Company (on behalf of Incyte Corporation),Other,Application,2019-04-24T04:00:00Z,2019,4,2019-04-24T04:00:00Z,,2019-04-24T14:55:58Z,,0,0,0900006483beaef4